ClinicalTrials.gg
RecruitingNCT07137637Updated Jul 23, 2026

HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

A Phase 1 interventional study of HPB-092 tablet in Relapsed and Refractory Acute Myeloid Leukemia (RR-AML), sponsored by Hangzhou Polymed Biopharmaceuticals, Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Primary conditionLeukemia, Myeloid, AcuteRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Leukemia, Myeloid, Acute.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hangzhou Polymed Biopharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
181st of 433
60 · median 50
Started
2026
with 55 others
Phase 1
121 of 473
69 open now
Primary completion
2027-06
later than 171 of 288 live
Registered
389th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 181st largest by planned enrollment of the 433 interventional ones that give a count, is one of 56 that started in 2026, is one of 121 in phase 1, reaches primary completion later than 171 of the 288 other live ones, and was the 389th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

259 more — sign in →

All 265 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved selectivity, potentially reducing toxicity. Its highly selective and potent inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) may provide additional therapeutic benefits that could enhance treatment efficacy and durability for patients with relapsed or refractory acute myeloid leukemia (RR-AML), further improving clinical outcomes in this population. HPB-092 also has a favorable safety profile, with no major risks identified in preclinical studies.

Phas 1 Study Outline:

  1. This is a multicenter, open-label, phase 1 study to evaluate the safety and efficacy of oral HPB-092 as monotherapy in patients with RR-AML.
  2. The study aims to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy.
  3. It consists of two parts: Part A for dose escalation and Part B for dose expansion, involving single or multiple doses.
  4. Patients must be diagnosed with morphologically documented RR-AML according to World Health Organization (WHO) 2022 criteria.
  5. Baseline assessments will include RR-AML with FLT3 mutations, spliceosome mutations in SF3B1 and U2AF1, as well as other biomarkers, which will be monitored throughout the study.
Read the detailed description

HPB-092 - A Novel Dual Selective Kinase Inhibitor of FLT3 and IRAK4:

Multiple FLT3 inhibitors have been approved for clinical use in acute myeloid leukemia (AML). However, many patients do not benefit from these therapies due to toxicities and resistance. IRAK4 is a serine/threonine kinase involved in innate immune signaling. Overexpression of IRAK4-particularly the long isoform (IRAK4-L)-is common in most AML cases and is associated with poor prognosis and resistance to FLT3 inhibitors, suggesting that dual inhibition of FLT3 and IRAK4 may provide therapeutic benefits.

HPB-092 is an effective dual inhibitor of FLT3 and IRAK4, exhibiting high selectivity, favorable absorption, distribution, metabolism, and excretion (ADME) properties, as well as strong anti-leukemic efficacy. It also has a broader safety window in non-clinical studies compared to existing FLT3 inhibitors. Given its potential to address unmet medical needs in RR-AML patients, particularly those resistant to existing FLT3 inhibitors, HPB-092 warrants further clinical investigation.

Primary Objective and Endpoints:

The primary objective of this Phase 1 study is to evaluate the safety and tolerability of HPB-092 monotherapy in patients with RR-AML. The primary endpoints will include assessments of adverse events (AEs), treatment-emergent adverse events (TEAEs), dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD).

Secondary Objectives:

The secondary objectives of this Phase 1 study are as follows:

  1. To characterize the pharmacokinetic profile of HPB-092.
  2. To determine the minimum safe dose and Biologically Effective Dose (BED) of HPB-092.
  3. To evaluate the anti-leukemic activity of various dose levels of HPB-092.
  4. To establish the Recommended Phase 2 Dose (RP2D) of HPB-092 in patients with RR-AML.

Exploratory Objectives:

The exploratory objectives will focus on the clinical pharmacology of HPB-092, including the identification of potential biomarkers to predict the response to HPB-092 in AML patients.

Part A Dosing Protocol:

HPB-092 is available in tablet form, with two strengths: 10 and 40 milligrams (mg). In Part A of the dose escalation, the starting dose will be 30 mg administered twice daily (BID), with subsequent dose escalations planned up to five dose levels. This approach aims to determine the Recommended Expansion Dose (RED) for the Part B dose expansion cohorts. Each treatment cycle will last 28 days and may be repeated in the absence of DLT or other toxicities, as determined by the investigator. Patients who derive clinical benefit from the study treatment may continue for up to two years from the initiation of the study drug or until one or more treatment discontinuation criteria are met.

In each dose escalation cohort, patients with RR-AML will be enrolled at the designated dose. Dose escalation will follow modified 3+3 rules, with DLT assessed during the first cycle. Escalation to the next dose level will occur as soon as the safety of the current dose is confirmed in a Cohort Review Meeting. The dose and schedule of HPB-092 administered to each patient will be documented on the appropriate form for each cycle.

Part B Dosing Protocol:

The Part B expansion, consisting of up to 3 dose levels, will begin once the recommended expansion doses (RED) is established based on the maximum tolerated dose (MTD) determined in Part A. This Part B expansion aims to further evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HPB-092, as well as to determine the recommended phase II dose (RP2D). The RP2D will be reviewed by a Cohort Review Meeting based on the results from Part B, considering all aspects of safety, tolerability, biological activity, pharmacokinetics, and preliminary efficacy in the trial population. The intent of the RP2D is to establish recommended dose levels and dosing intervals for the Phase II study, maximizing the potential for clinical benefit while minimizing the risk of toxicity. The Cohort Review Meeting may request the recruitment of additional patients at any previously explored or intermediate dose level to make an appropriate RP2D decision for the Phase 2 study.

Ethical Conduct of the Study:

The study will be conducted in accordance with the protocol, ICH guidelines, and applicable regulations governing clinical study conduct. Additionally, it will adhere to ethical principles derived from the Declaration of Helsinki.

03

Conditions studied

  • Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)

Browse trials for

Keywords

  • Interleukin-1 receptor-associated kinase 4 (IRAK4)
  • SF3B1
  • U2AF1
  • FLT3 mutation
  • FLT3 inhibitor
  • IRAK4 inhibitor
  • Dual Kinase Inhibitor FLT3 and IRAK4
  • Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
  • Acute Myeloid Leukemia (AML)
04

In context

Leukemia, Myeloid, Acute Reclassified

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

This study's planned enrollment of 60 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

This is the only study on the registry with Hangzhou Polymed Biopharmaceuticals, Inc. as lead sponsor.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for enrollment in the study:

  1. The patient must have a diagnosis of morphologically documented acute myeloid leukemia (AML) according to the World Health Organization (WHO) 2022 criteria, and must meet one of the following conditions:

    Relapsed Disease: Bone marrow blasts ≥ 5%; or Reappearance of blasts in the peripheral blood in at least two separate samples taken at least one week apart; or Development of extramedullary disease. Refractory Disease: Failure to achieve CR, CRh, or CRi at the response landmark (e.g., after 2 courses of intensive induction therapy), or Failure to achieve remission by a defined landmark, e.g., 180 days after initiation of less intensive therapy.

  2. The patients should have a stable transfusion requirement prior to enrollment as specified in the protocol.
  3. Male or non-pregnant, non-lactating female patients aged 18 years or older.
  4. The patient is not suitable for other known therapies that have clinical benefits for the disease.
  5. of ≥12 weeks, and (ECOG) performance status of 0 to 2.
  6. Renal Function: Serum creatinine \<1.5× the (ULN) or Estimated ≥ 60 mL/min as calculated using a standard method [Cockcroft-Gault formula, Modification of Diet in Renal Disease () equation, or estimated glomerular filtration rate (eGFR) calculation]. Liver Function: Total serum ≤1.5× ULN unless the patient has liver involvement by the primary disease (≤3× ULN); and and ALT ≤2.5× ULN unless the patient has hepatic (≤5× ULN). Cardiac Function: (LVEF) >50% as measured by echocardiogram or MUGA scan.
  7. Acute effects of any prior therapy must be resolved to baseline severity or Grade ≤ 1 per v5.0, except for adverse events (AEs) that do not constitute a safety risk according to the investigator's judgment.
  8. For females of , a serum pregnancy test must be negative within 7 days before enrollment.
  9. Male and female patients of childbearing potential who are at risk for pregnancy must agree to use at least two highly effective methods of throughout the study and for at least 90 days (or 180 days if required by local regulations) after the last dose of the assigned treatment.
  10. The interval from prior treatment to the time of study drug administration must be at least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast cells), or at least 5 half-lives for prior experimental agents or noncytotoxic agents.
  11. The patient must have the ability to understand and be willing to sign the informed.

Exclusion criteria

Exclusion Criteria:

Patients with any of the following characteristics/conditions will not be able to enroll in the study:

  1. Diagnosed with acute promyelocytic leukemia (APL) or BCR-ABL-positive leukemia.
  2. The patient has had a other than AML within the past five years as specified in the protocol.
  3. The patient has persistent non-hematological toxicities of ≥ Grade 2 (per v5.0) from prior treatment.
  4. History of Hematopoietic Stem Cell Transplant () as specified in the protocol.
  5. The patient has clinically active central nervous system (CNS) leukemia.
  6. The patient has a disseminated intravascular coagulation (DIC) abnormality.
  7. Recent surgery or radiation therapy as specified in the protocol.
  8. History of Class 3 or more severe heart failure according to classification, or (LVEF) below 45%, or Fridericia- interval (QTcF) > 450 ms at screening.
  9. The patient has hypokalemia or hypomagnesemia at screening.
  10. The patient requires treatment with drugs that are strong inhibitors or inducers of or P-glycoprotein (P-gp) as specified in the protocol.
  11. Active (GVHD) and treatment as specified in the protocol.
  12. Use of systemic or immunosuppressive drugs as specified in the protocol.
  13. The patient is known to be infected with (HIV), active or C, or other active hepatic disorders. The patient has an active uncontrolled infection.
  14. The patient has any condition that, in the investigator's opinion, makes the patient unsuitable for study participation.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    HPB-092 Monotherapy - Dose Escalation and Expansion

    RR-AML patients receive HPB-092 tablet monotherapy BID daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: HPB-092 tablet

Interventions

  • DrugHPB-092 tablet

    HPB-092 is formulated as a tablet for oral administration, taken twice daily (BID) over consecutive 28-day cycles. This novel small molecule selectively inhibits both FLT3 and interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 plays a crucial role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in acute myeloid leukemia (AML) and other malignancies.

07

What researchers measure

Primary outcomes

  1. Adverse Events and Treatment-Emergent Adverse Events [Safety and Tolerability]

    Adverse events (AEs) and treatment-emergent adverse events (TEAEs) will be measured by the number of participants who have received at least one dose of HPB-092. All AEs and TEAEs will be assessed and reported in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From the first dose (Cycle 1 day 1) of HPB-092 treatment until 28 days after the completion of treatment, or after early termination or withdrawal from the study, with a duration of up to 24 months

  2. Dose-Limiting Toxicity [Safety and Tolerability]

    The Dose-Limiting Toxicity (DLT) will be determined based on the first cycle (Days 1-28) of HPB-092 in RR-AML patients. Reviews of DLT for dose escalation decisions will be conducted for each completed dose level. Dose escalation decisions will require full safety data review of all subjects who completed Cycle 1 (Days 1-28) or discontinued due to a suspected DLT within Cycle 1 (Days 1-28).

    Time frame: Days 1-28 of the first cycle (each cycle is 28 days)

  3. Maximum Tolerated Dose [Safety and Tolerability]

    The Maximum Tolerated Dose (MTD) is defined as the highest dose level at which ≤1 of 6 evaluable RR-AML subjects (≤33%) experience a DLT during Cycle 1 (Days 1-28). If ≥2 DLTs occur at a given dose level, the preceding dose will be expanded to 6 additional subjects for MTD confirmation. All subjects must complete the DLT observation period (Cycle 1, Days 1-28) to be evaluable; early discontinuations due to non-DLT reasons will be replaced.

    Time frame: Days 1-28 of the first cycle (each cycle is 28 days)

Secondary outcomes

  1. Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by the maximum plasma concentration (Cmax), in AML patients.

    Maximum plasma concentration (Cmax) in AML patients

    Time frame: Up to 24 months

  2. Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by Time to maximum plasma concentration (Tmax), in AML patients

    Time to maximum plasma concentration (Tmax) in AML patients

    Time frame: Up to 24 months

  3. Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by Area under the plasma concentration versus time curve (AUC) [0-24], in AML patients

    Area under the plasma concentration-time curve from 0 to 24 hours in AML patients

    Time frame: Up to 24 months

  4. Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by Area under the plasma concentration versus time curve (AUC) [0-inf], in AML patients

    Area under the plasma concentration-time curve from 0 to infinity in AML patients

    Time frame: Up to 24 months

  5. Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by Plasma terminal elimination half-life (T1/2), in AML patients

    Plasma terminal elimination half-life (T1/2) in AML patients

    Time frame: Up to 24 months

  6. Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by the plasma clearance (CL), in AML patients.

    Calculation of the clearance (CL) of HPB-092 in AML patients, determined by the plasma drug concentration-time curve area under the curve (AUC) and the administered dose.

    Time frame: Up to 24 months

  7. Assessment of the Efficacy of Clinical Response to HPB-092 Monotherapy in AML Patients.

    Definitions for treatment response will follow the 2022 recommendations for the diagnosis and management of AML in adults from an international expert panel on behalf of the European LeukemiaNet (ELN). The clinical response to HPB-092 monotherapy in AML patients will be evaluated by determining the percentage of patients who achieve any of the following outcomes: complete remission (CR), complete remission with partial hematologic recovery (CRh), complete remission with incomplete hematologic recovery (CRi). The Disease Control Rate (DCR) is defined as the confirmed remission rate, encompassing all complete responses (CR + CRh + CRi) in AML patients.

    Time frame: up to 24 months

  8. Assessment of the Duration of Response to HPB-092 Monotherapy in AML Patients.

    Assessed by the Duration of Response (DoR) to HPB-092 monotherapy in AML patients. The DoR is defined as the time from the first documentation of a complete response (CR, CRh, or CRi) until the first occurrence of disease progression or relapse in AML patients.

    Time frame: Up to 24 months

  9. Assessment of the Time to Response to HPB-092 Monotherapy in AML Patients.

    Time to Response (TTR) is defined as the duration from the initiation of HPB-092 monotherapy to the first documentation of a clinical response (including CR, CRh, or CRi) in AML patients.

    Time frame: Up to 24 months

  10. Determination of the Recommended Phase 2 Dose (RP2D) of HPB-092 Monotherapy in AML Patients.

    The Recommended Phase 2 Dose (RP2D) will be determined during the Cohort Review Meeting, taking into account all aspects of safety, tolerability, biological activity, pharmacokinetics, and preliminary efficacy within the trial population. The aim of establishing an RP2D is to identify a dose and schedule that optimize the potential for clinical benefit while minimizing the risk of toxicity in AML Patients.

    Time frame: Up to 24 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 14 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 22, 2025
StartActual
Apr 10, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07137637
Lead sponsor
Hangzhou Polymed Biopharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Apr 10, 2026
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

YONG GUO, MD
Contact
yong.guo@polymedbiopharma.com
+8613480793536
He Zhou, MD/PhD
Contact
he.zhou@polymedbiopharma.com
Jianxiang Wang, MD
principal investigator · Institute of Hematology and Blood Diseases Hospital, Tianjin, China

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion